Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Deferred Taxes (2020 - 2025)

Neurocrine Biosciences' Deferred Taxes history spans 6 years, with the latest figure at $48.2 million for Q4 2025.

  • For Q4 2025, Deferred Taxes rose 253.99% year-over-year to $48.2 million; the TTM value through Dec 2025 reached $165.4 million, up 234.36%, while the annual FY2025 figure was $165.4 million, 234.36% up from the prior year.
  • Deferred Taxes reached $48.2 million in Q4 2025 per NBIX's latest filing, down from $168.3 million in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $168.3 million in Q3 2025 to a low of -$41.5 million in Q2 2023.
  • Average Deferred Taxes over 5 years is $450000.0, with a median of -$4.4 million recorded in 2021.
  • Peak YoY movement for Deferred Taxes: tumbled 10433.33% in 2023, then skyrocketed 582.23% in 2025.
  • A 5-year view of Deferred Taxes shows it stood at -$4.7 million in 2021, then surged by 387.23% to $13.5 million in 2022, then skyrocketed by 52.59% to $20.6 million in 2023, then crashed by 251.94% to -$31.3 million in 2024, then surged by 253.99% to $48.2 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Deferred Taxes are $48.2 million (Q4 2025), $168.3 million (Q3 2025), and -$37.4 million (Q2 2025).